T. Rowe Price Associates

Activity in this selectionBiotech

By stage

Series C+2

Series A1

Biotech3

United States2

Australia1

3 in this selection

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Feb 4

Develops novel multifunctional antibodies for oncology and immunology & inflammation indications

$52MSeries A+

Role not disclosed

Jan 8

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F

Role not disclosed